Can a new injection shrink nasal polyps and restore easy breathing?
NCT ID NCT06930612
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This phase II trial is testing an experimental biologic called CM512 in about 120 people with chronic rhinosinusitis and nasal polyps—non-cancerous growths that block the nose and cause congestion. Participants receive either CM512 or a placebo as a subcutaneous injection, and researchers track changes in nasal polyp size, congestion, and overall symptoms over 24 weeks. The goal is to see if CM512 can reduce polyp burden and improve quality of life, potentially offering a new treatment option for this difficult-to-manage condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CM512, an experimental biologic given by injection under the skin
- What this could lead to
- If it works, CM512 could offer a new non-surgical option to shrink nasal polyps and improve breathing and quality of life for people with chronic sinusitis.
- What could go wrong
- This is an early phase II study with only 120 participants, so results may not hold up in larger trials. As a biologic injection, it may cause side effects or fail to beat placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
120 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Jul 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * with chronic rhinosinusitis with nasal polyposis (CRSwNP). * Nasal Polyp Score (NPS) of ≥5 with a minimum score of 2 in each nasal cavity. * Nasal Congestion Score of 2 or 3 at screening period, and at least 2 at baseline. * Contraception. Exclusion Criteria: * Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for biologic therapy/systemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity. * Vaccination with live attenuated vaccine within 30 days before randomization or during the planned study period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis with nasal polyposis are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tong-Ren hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.